Citi analyst Geoff Meacham raised the firm’s price target on Gilead (GILD) to $140 from $135 and keeps a Buy rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead assumed with Buy from Neutral at UBS
- Gilead Sciences: PrEP-Led Growth, Easing HIV Overhangs, and Pipeline Upside Support Buy Rating and 2027 Re-Rating Target
- Repare Therapeutics announces Gilead to acquire RP-3467 for up to $30M
- Early notable gainers among liquid option names on December 23rd
- Trump Trade: Trump strikes deals with nine drugmakers to cut prices